Leading Infectious Disease Biomaterial Manufacturer

Copan FLOQSwab® and Liquid Control Products
- Clinical Diagnostics,
- Proficiency Programs,
- Training, Verification and Development
Antigens for Diagnostic Test Manufacturers
Viral Transport Medium – DxTM™

Microbix Schedules Release of Results for Q2 Fiscal 2025

Microbix announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 ended March 31, 2025 (“Q2 2025”) prior to the start of trading on May 15, 2025.

Microbix’s Corporate Presentation

Profitable growth from supporting next generation Diagnostics. Click below to download..

Microbix’s Clot-Buster Drug Project Advances

Microbix announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the formulated and packaged drug (i.e., “Drug Product”) of Kinlytic® urokinase (“Kinlytic”), a biologic drug for dissolving blood clots.

QAPS

Why choose Microbix Quality Assessment Products (QAPs)? Find out more.

infectious-diseas-antigens-3_55600834-e67d-4aa2-ad6b-59096ce3b3c8

INFECTIOUS DISEASE ANTIGENS

Microbix produces one of the world’s broadest range of infectious disease antigens.

PARTNERSHIP OPPORTUNITIES

Microbix has a partnership opportunity. Check it out here.

Our Commitment to Quality

Our quality process ensures our customers receive products that meet and exceed their needs and expectations. Our quality management system takes into consideration regulatory requirements that are applicable to the type of products we manufacture and the industries we serve.